Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model

In Vivo

Volumn 25, Issue 6, 2011, Pages 887-893

  Kim, Young ^a   Schmidt, Matthias ^a   Endo, Tomoyuki ^b,c   Lu, Desheng ^b   Carson, Dennis ^b   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta catenin; Myeloma; Signal transduction; Signaling therapies; Wnt pathway

Indexed keywords

BETA CATENIN; CICLOPIROXOLAMINE; DOXORUBICIN; LENALIDOMIDE; THALIDOMIDE; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MOUSE; MYELOMA; NONHUMAN; OVERALL SURVIVAL; TREATMENT OUTCOME;

EID: 80755142841     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cadigan KM and Liu YI: Wnt signaling: complexity at the surface. J Cell Sci 119(Pt 3): 395-402, 2006.
2. Miller JR, Hocking AM, Brown JD and Moon RT: Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways. Oncogene 18(55): 7860-7872, 1999. (Pubitemid 30066232)
3. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157(3): 429-440, 2002. (Pubitemid 34839807)
4. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
5. Moon RT, Kohn AD, De Ferrari Gv and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004. (Pubitemid 39150127)
6. Nusse R: Wnt signaling in disease and in development. Cell Res 15: 28-32, 2005.
7. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
8. Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404, 2006. (Pubitemid 43830647)
9. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci 101: 3118-3123, 2004. (Pubitemid 38327744)
10. Tew KD, Bomber AM and Hoffman SJ: Ciclopirox olamine and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48(13): 3622-3625, 1988.
11. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC and Hube B: Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob. Agents Chemother 47(6): 1805-1817, 2003. (Pubitemid 36637799)
12. Schmidt M, Sievers E, Endo T, Lu D, Cason D and Schmidt-Wolf IGH: Targeting Wnt pathway in lymphoma and myeloma cells. Brit J Haematol 144(5): 796-798, 2009.
13. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ciclopirox olamine exhibitis selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PloS one 4(12): e8294, 2009.
14. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B and Shaughnessy JD Jr: The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109(10): 4470-4477, 2007. (Pubitemid 46743417)
15. Knobloch J and Rüther U: Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7(9): 1121-1127, 2008. (Pubitemid 351749260)
16. Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D and Schmidt-Wolf IGH: Increased efficacy of lenalidomide and thalidomide by addition of griseofulvin targeting the Wnt pathway. Leuk Res Nov 26, 2010.
17. Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D and Schmidt-Wolf IGH: Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 25(1): 99-103, 2011.
18. Schmidt M, Kim Y, Gast S-M, Endo T, Lu D, Carson D, Kipps T and Schmidt-Wolf IGH: Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo. In press.
19. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC and Carrasco DR: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104(18): 7516-7521, 2007. (Pubitemid 47185938)